Results 11 to 20 of about 43,064 (280)

A Pragmatic Approach to Susceptibility Classification of Yeasts without EUCAST Clinical Breakpoints [PDF]

Journal of Fungi, 2022
EUCAST has established clinical breakpoints for the six most common Candida species and Cryptococcus neoformans but not for less common yeasts because sufficient evidence is lacking. Consequently, the question “How to interpret the MIC?” for other yeasts
Karen Marie Thyssen Astvad, Sevtap Arikan-Akdagli, Maiken Cavling Arendrup   +2 more
doaj   +4 more sources

Sequence homology at the breakpoint and clinical phenotype of mitochondrial DNA deletion syndromes. [PDF]

PLoS ONE, 2010
Mitochondrial DNA (mtDNA) deletions are a common cause of mitochondrial disorders. Large mtDNA deletions can lead to a broad spectrum of clinical features with different age of onset, ranging from mild mitochondrial myopathies (MM), progressive external ...
Bekim Sadikovic, Jing Wang, Ayman W El-Hattab, Megan Landsverk, Ganka Douglas, Ellen K Brundage, William J Craigen, Eric S Schmitt, Lee-Jun C Wong   +8 more
doaj   +6 more sources

Correction: Sequence Homology at the Breakpoint and Clinical Phenotype of Mitochondrial DNA Deletion Syndromes. [PDF]

PLoS ONE, 2017
[This corrects the article DOI: 10.1371/journal.pone.0015687.].
Bekim Sadikovic, Jing Wang, Ayman W El-Hattab, Megan Landsverk, Ganka Douglas, Ellen K Brundage, William J Craigen, Eric S Schmitt, Lee-Jun C Wong   +8 more
doaj   +4 more sources

The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach. [PDF]

Clinical Microbiology and Infection, 2012
Item does not contain fulltextClinical breakpoints are used in clinical microbiology laboratories to categorize microorganisms as clinically susceptible (S), intermediate (I) or resistant (R) dependent on the quantitative antimicrobial susceptibility as ...
C.-J. Soussy, M. Steinbakk, Soussy, C-J, Brown, D.F.J., Steinbakk, M., A.P. MacGowan, Rodloff, A., Mouton, JW, Ivanova, M., Kahlmeter, G., Steinbakk, M, M. Ivanova, Soussy, C.-J., G. Kahlmeter, Rodloff, A, Apfalter, P, Giske, CG, J.W. Mouton, Soussy, C.J., A. Rodloff, Giske, C.G., Ivanova, M, Mouton †, J.W., R. Cantón, Apfalter, P., Canton, R, Canton, R., MacGowan, A.P., C.G. Giske, P. Apfalter, MacGowan, AP, Mouton, J.W., Brown, D.F., D.F.J. Brown, Brown, DFJ   +34 more
core   +4 more sources

Strategy for breakpoint cluster region analysis in chronic myelocytic leukemia in a routine clinical laboratory

American Journal of Clinical Pathology, 1990
Despite the increasing reliance on breakpoint cluster region (bcr) determinations in diagnosis of chronic myelocytic leukemia (CML), few reports have dealt with the practical aspects of specimen analysis. In the setting of a routine molecular diagnostics
Childs, C. C., Trujillo, J. M., Kantarjian, H. M., Cork, A., Haber, L. M., Stass, S. A., Hirsch-Ginsberg, C., Nellis, K.   +7 more
core   +6 more sources

Diagnostic utility of GenoType MTBDRsl assay for the detection of moxifloxacin-resistant mycobacterium tuberculosis, as compared to phenotypic method and whole-genome sequencing

International Journal of Mycobacteriology, 2022
Background: Recently, moxifloxacin (MFX)-resistant results of Mycobacterium tuberculosis (Mtb) obtained by GenoType MTBDRsl (second-line line probe assay [SL-LPA]) have been stratified to determine their resistance level; however, its accuracy has not ...
Raj Narayan Yadav, Manpreet Bhalla, Gavish Kumar, Grish C Sah, Ravindra Kumar Dewan, Ritu Singhal   +5 more
doaj   +1 more source

Evaluations of Antifungal Susceptibilities Have to Be According to Reference Guidelines: CLSI and EUCAST

Van Tıp Dergisi, 2022
Editöre mektup olduğundan özet ...
Ali Korhan Sığ
doaj   +1 more source

Population Pharmacokinetics of Intravenous Amoxicillin Combined With Clavulanic Acid in Healthy and Critically Ill Dogs

Frontiers in Veterinary Science, 2021
Background: Data regarding antimicrobial pharmacokinetics (PK) in critically ill dogs are lacking and likely differ from those of healthy dogs. The aim of this work is to describe a population PK model for intravenous (IV) amoxicillin–clavulanic acid ...
Maria D. Vegas Cómitre, Stefano Cortellini, Marc Cherlet, Mathias Devreese, Beatrice B. Roques, Alain Bousquet-Melou, Pierre-Louis Toutain, Pierre-Louis Toutain, Ludovic Pelligand, Ludovic Pelligand   +9 more
doaj   +1 more source

Understanding and Addressing CLSI Breakpoint Revisions: a Primer for Clinical Laboratories [PDF]

Journal of Clinical Microbiology, 2019
The Clinical and Laboratory Standards Institute (CLSI) has revised several breakpoints since 2010 for bacteria that grow aerobically. In 2019, these revisions include changes to the ciprofloxacin and levofloxacin breakpoints for the Enterobacteriaceae and Pseudomonas aeruginosa , daptomycin ...
Romney M, Humphries, April N, Abbott, Janet A, Hindler   +2 more
openaire   +2 more sources

Updated EUCAST Clinical Breakpoints against Aspergillus, Implications for the Clinical Microbiology Laboratory [PDF]

Journal of Fungi, 2020
Azole resistance poses a problem for the management of patients with invasive aspergillosis. Former species are in fact groups of closely related species (or complexes); cryptic species frequently show high antifungal resistance. The European Committee on Antimicrobial Susceptibility Testing (EUCAST) Definitive Document (E.Def) 9.3.2 includes ...
openaire   +4 more sources